This Article Full Text Full Text (PDF) All Versions of this Article: 35/9/2111    most recent 01.STR.0000136556.34438.b3v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weir, C. J. Search for Related Content PubMed PubMed Citation Articles by Weir, C. J. Pubmed/NCBI databases Substance via MeSH Related Collections Neuroprotectors

(Stroke. 2004;35:2111.)
© 2004 American Heart Association, Inc.

Original Contributions

Targeting Neuroprotection Clinical Trials to Ischemic Stroke Patients With Potential to Benefit From Therapy

Christopher J. Weir, PhD; Markku Kaste, MD Kennedy R. Lees, MD, FRCP for the Glycine Antagonist in Neuroprotection (GAIN) International Steering Committee and Investigators

From the Division of Cardiovascular and Medical Sciences (C.J.W., K.R.L.), University of Glasgow, Gardiner Institute, Western Infirmary, Glasgow, UK; the Department of Neurology (M.K.), Helsinki University Central Hospital, Helsinki, Finland; and the Robertson Centre for Biostatistics (C.J.W), University of Glasgow, Glasgow, UK.

Correspondence to Dr C.J. Weir, Division of Cardiovascular and Medical Sciences, University of Glasgow, Gardiner Institute, Western Infirmary, Glasgow G11 6NT, UK. E-mail c.j.weir{at}clinmed.gla.ac.uk

Background and Purpose— Clinical trials of neuroprotective drugs have had limited success. We investigated whether selecting patients according to prognostic features would improve the statistical power of a trial to identify an efficacious treatment.

Methods— Using placebo data from the Glycine Antagonist in Neuroprotection (GAIN) International and National Institute of Neurological Disorders and Stroke (NINDS) recombinant tissue plasminogen activator (rtPA) clinical trials, we developed and validated simple prognostic models for stroke trial end points: Barthel Index 95, modified Rankin Scale 1, National Institutes of Health Stroke Scale 1, and Glasgow Outcome Scale=1. Using these models, we simulated 1000 clinical trials and estimated, under several hypothetical treatment effect patterns of neuroprotection, the effect on statistical power of including only patients with moderate prognosis. We calculated the number of patients that would have to be enrolled to maintain the statistical power achieved in selecting the whole trial population. Reanalysis of actual data from the NINDS rtPA trials confirmed the results independently.

Results— Selecting patients with moderate prognosis (predicted probability of favorable outcome 0.2 to 0.8) enabled a sample size reduction, without loss of statistical power, of between 54.6% (51.3% to 57.6%) and 68.6% (66.0% to 71.1%), depending on the treatment effect pattern and outcome measure. These benefits were largely due to the exclusion of patients with poor prognosis.

Conclusions— Targeting patients with potential to benefit enables a substantial sample size reduction without compromising statistical power or duration of recruitment. As part of a broader trial design strategy, informed use of prognostic data available acutely would help in identifying effective neuroprotective treatments.

Key Words: clinical trials • neuroprotection • prognosis

This article has been cited by other articles:

				K.R. Lees, G.A. Ford, K.W. Muir, N. Ahmed, A.G. Dyker, S. Atula, L. Kalra, E.A. Warburton, J.-C. Baron, D.F. Jenkinson, et al. Thrombolytic therapy for acute stroke in the United Kingdom: experience from the safe implementation of thrombolysis in stroke (SITS) register QJM, August 11, 2008; (2008) hcn102v1. [Abstract] [Full Text] [PDF]

				I. R. Konig, A. Ziegler, E. Bluhmki, W. Hacke, P. M.W. Bath, R. L. Sacco, H. C. Diener, C. Weimar, and on behalf of the Virtual International Stroke Tria Predicting Long-Term Outcome After Acute Ischemic Stroke: A Simple Index Works in Patients From Controlled Clinical Trials Stroke, June 1, 2008; 39(6): 1821 - 1826. [Abstract] [Full Text] [PDF]

				K. R. Lees, J. A. Zivin, T. Ashwood, A. Davalos, S. M. Davis, H.-C. Diener, J. Grotta, P. Lyden, A. Shuaib, H.-G. Hardemark, et al. NXY-059 for Acute Ischemic Stroke N. Engl. J. Med., February 9, 2006; 354(6): 588 - 600. [Abstract] [Full Text] [PDF]

				M. Fisher and for the Stroke Therapy Academic Industry Roundtabl Enhancing the Development and Approval of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable Stroke, August 1, 2005; 36(8): 1808 - 1813. [Abstract] [Full Text] [PDF]

				F. B. Young, K. R. Lees, C. J. Weir, and for the GAIN International Trial Steering Committe Improving Trial Power Through Use of Prognosis-Adjusted End Points Stroke, March 1, 2005; 36(3): 597 - 601. [Abstract] [Full Text] [PDF]